Discovery of protein that fuels breast cancer growth could lead to targeted treatment

September 12, 2012
Discovery of protein that fuels breast cancer growth could lead to targeted treatment

(Medical Xpress)—Cancer Research UK scientists have discovered how a key protein fuels breast cancer growth by boosting numbers of cancer stem cells in tumours that have low levels of a protein called claudin, accounting for up to 10 per cent of all breast cancers.

This raises the prospect that treatments currently being developed to inhibit this key protein – called (TGF-beta) – could be used to treat this group of women, who tend to have poorer survival and for whom there are currently no targeted treatments.

The study is published in Nature Communications today.

Earlier this year the same team, from Cancer Research UK's Cambridge Research Institute, published a groundbreaking study showing that breast cancer was not one disease, but ten, each defined by its own unique ''.

In this study they used this knowledge to explore, for the first time, how the network of genes activated by TGF-beta differs among different types of breast cancer.

This revealed that, in cancers with low levels of the protein claudin, TGF-beta activates a specific network of genes that boosts the number of breast cancer – which promote cancer spread and are associated with poor survival.

TGF-beta does this through the regulation of two other proteins – Smad and SRF – and with the help of a third – NEDD9 – which helps to assemble the three into their active form.

Dr Alejandra Bruna, senior author on the study, said: "For years scientists have been puzzling how TGF-beta can be seen to both fuel and suppress the growth of cancer. And now, thanks to the improved understanding we are building of the different genetic types of , we can pinpoint one of the specific pathways that account for these differences."

Study leader Professor Carlos Caldas, added: "Crucially this study highlights the role of TGF-beta in one particular subtype that accounts for up to 10 per cent of all breast cancers. A number of promising treatments are already in early phase trials to target TGF-beta, meaning there is genuine hope of improved treatment options for this group of women in the near future. The next step will be to design the appropriate clinical trials."

Dr Julie Sharp, senior science information manager at Cancer Research UK, said: "This study provides us with important insights into TGF-beta's 'split personality' and how it can both prevent and fuel the growth of cancer cells. Our scientists have been at the forefront of research into the role of growth factors in cancer and it's immensely heartening to see this now paving the way for powerful new treatments with the potential to benefit patients."

Explore further: Study details on-off switch that promotes or suppresses breast cancer

More information: Bruna A. et al, TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer, Nature Communications, 2012, DOI: 10.1038/ncomms2039

Related Stories

Study details on-off switch that promotes or suppresses breast cancer

February 16, 2012
Signals can tell cells to act cancerous, surviving, growing and reproducing out of control. And signals can also tell cells with cancerous characteristics to stop growing or to die. In breast cancer, one tricky signal called ...

Beta Blockers could stop breast cancer spreading

September 30, 2011
(Medical Xpress) -- Cancer Research UK scientists are investigating whether beta-blockers hold the key to preventing breast cancer spread and improving survival. Promising early results will be presented on the eve of breast ...

Ovarian cancer cells hijack surrounding tissues to enhance tumor growth

September 4, 2012
Tumor growth is dependent on interactions between cancer cells and adjacent normal tissue, or stroma. Stromal cells can stimulate the growth of tumor cells; however it is unclear if tumor cells can influence the stroma.

Recommended for you

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.